<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162995">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01734096</url>
  </required_header>
  <id_info>
    <org_study_id>PZ00P3_121655</org_study_id>
    <nct_id>NCT01734096</nct_id>
  </id_info>
  <brief_title>Renal Response to Lower Body Negative Pressure in Pre-hypertensive States</brief_title>
  <official_title>Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. Grégoire Wuerzner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether in pre-hypertensive states such as white
      coat hypertension or obesity related hypertension, renal function is more sensitive to
      orthostatic stress.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>sodium excretion</measure>
    <time_frame>after one hour of lower body negative pressure</time_frame>
    <safety_issue>No</safety_issue>
    <description>sodium excretion will be compared to control group (healthy volunteers) after one hour of lower negative pressure. The protocol includes 2 hours of baseline measure, one hour of lower negative pressure and 2 hours of recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>after one hour of lower body negative pressure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>renal plasma flow</measure>
    <time_frame>after one hour of lower body negative pressure</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <condition>White Coat Hypertension</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obesity group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with BMI &gt;30 Kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>white coat hypertension group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with office blood pressure &gt;140/90 mmHg and ambulatory daytime blood pressure &lt;135/85 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lower body negative pressure (LBNP)</intervention_name>
    <description>Lower limbs are put in in LBNP device for one hour (-30 mbar)</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>obesity group</arm_group_label>
    <arm_group_label>white coat hypertension group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <description>candesartan cilexetil 16 mg once a day for 7 days cross over with placebo</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>obesity group</arm_group_label>
    <arm_group_label>white coat hypertension group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 30 Kg/m2 (obesity group)

          -  office BP &gt;140/90 and daytime ambulatory blood pressure &lt;135/85 (white coat
             hypertension group)

        Exclusion Criteria:

          -  History of allergic reaction

          -  Diabetes type 1 or type 2

          -  History of renal artery stenosis

          -  Acute illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service of nephrology and hypertension</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of nephrology and hypertension</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 10, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>PD Dr. Grégoire Wuerzner</investigator_full_name>
    <investigator_title>Doctord, MD, privat docent</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>obesity</keyword>
  <keyword>white coat hypertension</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
